Nanxin Pharmaceutical (688189) Company Comment: Influenced by multiple factors in 2021, performance in 2022 can be expected
Nanxin Pharmaceutical (688189): Short-term performance is disrupted by the epidemic, and long-term trends in innovation layout are improving
Nanxin Pharmaceutical (688189): Brilliant performance in 2020, strong performance of peramivir injections, many highlights in 2021
Nanxin Pharmaceutical (688189): profit side performance much better than expected Paramivir injection strong performance more interesting in 2021
First coverage report of Nanxin Pharmaceutical (688189): 10 billion peramivir+billions of rabies monoclonal anti-influenza stars towards a brilliant future
Nanxin Pharmaceutical (688189): Steady growth in performance and steady progress in new drug development
Nanxin Pharmaceutical (688189): performance in line with expectations and good profit prospects
Nanxin Pharmaceutical (688189): a fast-growing new star in the field of anti-influenza in China
Science and Technology Innovation Board purchase Strategy-Nanxin Pharmaceutical (688189)
Science and Technology Innovation Board Medical Biology Series: Nanxin Pharmaceutical (688189)
No Data